Clinical Technology
Adult Immunization
Hepatology
Pediatric Immunization
Screening
Psychiatry
Allergy
Women's Health
Cardiology
Pediatrics
Dermatology
Endocrinology
Pain Management
Gastroenterology
Geriatrics
Infectious Disease
Obesity Medicine
Rheumatology
Oncology
Nephrology
Neurology
Pulmonology

Adult Immunization Allergy & Immunology Cardiology Dermatology Endocrinology Gastroenterology Infectious Disease Men’s Health Nephrology Neurology Pain Management Pediatric Immunization Pediatrics Psychiatry Pulmonology Rheumatology Screening Women’s Health

Billing and Collections Career Planning Coding and Documentation Concierge Medicine Cybersecurity EHRs Investing Patient Relations Personal Finance Practice Management Remote Patient Monitoring Staffing Technology Telehealth Value-based Care

VMS and Menopause Atopic Dermatitis Provider Toolkit Adult Immunization Provider Toolkit Dermatology Hot Topics

Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from Albany Medical Center : Episode 6

Comprehensive Antibody Screening in T1D: Understanding Types and Relevance

May 10, 2024

Opinion

Video

EP: 1.Clinical Insights: Addressing the Impact of Type 1 Diabetes (T1D) Burden

EP: 2.Navigating T1D: From Complications to Stage Progression

EP: 3.Understanding T1D Progression: The Importance of Recognizing Different Stages

EP: 4.Optimizing T1D Care: Collaborative Approaches and Expert Insights

EP: 5.Antibody Screening in T1D: Identifying High-Risk Populations and Best Screening Practices

EP: 6.Comprehensive Antibody Screening in T1D: Understanding Types and Relevance

EP: 7.Emphasizing Early T1D Intervention: Avoiding Complications Associated with Delayed Treatment

EP: 8.Delaying T1D Progression: Strategies and Interventions for Optimal Management

EP: 9.Insights from the TN-10 Study and its Impact on T1D Stage Progression

EP: 10.Optimizing the Teplizumab Infusion Process: The Vital Role of Key Contacts and Champions

EP: 11.Key Messages and Strategies: Managing and Following Up Patients Receiving Teplizumab

Related Videos

Related Content

Joint FDA Studies Show DermaSensor Device Reduces Missed Skin Cancers in Primary Care by 50% / Image credit: ©Pixel-Shot/AdobeStock

Joint FDA Studies Show DermaSensor Device Reduces Missed Skin Cancers in Primary Care by 50%

Sydney Jennings

FDA-cleared DermaSensor device shows 96% sensitivity and reduces missed skin cancer diagnoses by 50% in primary care, according to new data.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Older Adults are Open to Cognitive Assessment for Dementia in Primary Care But Obstacles Loom Large, a New Study Finds / image credit © Andrey Popov

Older Adults are Open to Cognitive Assessment for Dementia in Primary Care But Obstacles Loom Large, a New Study Finds

A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.

Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation

Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation

Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.

ctDNA Blood Test Showed High Sensitivity, Specificity for Colorectal Cancer but Poor Sensitivity for Advanced Precancerous Neoplasia / image credit ©Andrey Popov/stock.adobe.com

ctDNA Blood Test Showed High Sensitivity, Specificity for Colorectal Cancer but Poor Sensitivity for Advanced Precancerous Neoplasia

A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.

OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer

OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer

Sydney Jennings

ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.

Related Content

Joint FDA Studies Show DermaSensor Device Reduces Missed Skin Cancers in Primary Care by 50% / Image credit: ©Pixel-Shot/AdobeStock

Joint FDA Studies Show DermaSensor Device Reduces Missed Skin Cancers in Primary Care by 50%

Sydney Jennings

FDA-cleared DermaSensor device shows 96% sensitivity and reduces missed skin cancer diagnoses by 50% in primary care, according to new data.

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Weekly Dose: A Roundup of Top Stories for Primary Care Physicians

Sydney Jennings

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Older Adults are Open to Cognitive Assessment for Dementia in Primary Care But Obstacles Loom Large, a New Study Finds / image credit © Andrey Popov

Older Adults are Open to Cognitive Assessment for Dementia in Primary Care But Obstacles Loom Large, a New Study Finds

A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.

Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation

Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation

Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.

ctDNA Blood Test Showed High Sensitivity, Specificity for Colorectal Cancer but Poor Sensitivity for Advanced Precancerous Neoplasia / image credit ©Andrey Popov/stock.adobe.com

ctDNA Blood Test Showed High Sensitivity, Specificity for Colorectal Cancer but Poor Sensitivity for Advanced Precancerous Neoplasia

A new study of a circulating tumor DNA-based screening test revealed promising sensitivity and specificity for for CRC, but only 12.5% sensitivity for advanced neoplasia.

OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer

OASIS-4 Trial: Elinzanetant Reduces Frequency of Vasomotor Symptoms Related to Endocrine Therapy for HR-Positive Breast Cancer

Sydney Jennings

ASCO 2025. Elinzanetant significantly reduced the frequency of VMS vs placebo in women on endocrine therapy for treatment or prevention of HR+ breast cancer.

Editorial Board

Terms and Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.